This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Nuclear mitochondrial myopathies panels [69 genes]
Metabolic myopathies are a group of secondary hereditary muscle diseases of enzymatic defects that affect the metabolic process and production of muscle energy. Some of them are considered to be inborn errors of metabolism and, even though they are rare causes of myopathy, their diagnostic importance lies in that some of them are potentially treatable.
Symptomatology may be similar to other forms of muscular dystrophy or inflammatory myopathies, usually with subtle symptoms, such as asymptomatic elevation of CPK, muscle cramps, myalgia, or myoglobinuria. Their prevalence is unknown: Pompe disease (acid maltase deficiency) affects 1 in 40,000 and McArdle disease 1 in 100,000 individuals.
Their etiology is related to problems in the metabolism of glycogen, lipids, or mitochondrial oxidation. Because of this, we have designed three specific panels for each metabolic pathway and a comprehensive panel that contemplates all of the implicated genes as a whole.
Steps to follow
How to order
1. Download & fill out
Please cover as many fields as possible in both documents
2. Sample collection
Three sample types: saliva, peripheral blood or genomic DNA
3. Pack the sample
Please pack the sample in a way to prevent leakage
4. Send the sample & the request
Please schedule the delivery for Mon–Thur: 8am – 5pm
5. Result: the report
Via: Client Site HIC / Client Site Imegen / Certified email
Solicita información de
Nuclear mitochondrial myopathies panels
Turnaround time (TAT): 6 weeks
Ref. S-202008622
- AARS2
- ACAD9
- AGK
- AIFM1
- BCS1L
- C12orf65
- C1QBP
- CASQ1
- CHCHD10
- CHKB
- COQ2
- COQ8A
- COQ9
- COX10
- COX15
- COX6A2
- DGUOK
- EARS2
- ECHS1
- ETHE1
- FARS2
- FBXL4
- FDX2
- FOXRED1
- GFER
- GFM1
- HADHA
- HADHB
- IARS2
- ISCU
- LIPT1
- LRPPRC
- MGME1
- MICU1
- MSTO1
- NDUFA9
- NDUFAF6
- NDUFS4
- OPA1
- PDHA1
- PDHB
- PDHX
- PNPLA8
- PNPT1
- POLG
- POLG2
- PUS1
- RNASEH1
- RRM2B
- SCO2
- SDHA
- SDHAF1
- SLC19A3
- SLC25A3
- SLC25A32
- SLC25A4
- SLC25A42
- SUCLA2
- SUCLG1
- SURF1
- TAZ
- TK2
- TMEM126B
- TMEM65
- TSFM
- TTC19
- TWNK
- TYMP
- YARS2
Priority Genes : Genes where there is sufficient evidence (clinical and functional) to consider them associated with the disease; they are included in the clinical practice guidelines.
Secondary Genes: Genes related to the disease, but with a lower level of evidence or that constitute sporadic cases.
* Candidate Genes: Not enough evidence in humans, but potentially associated with the disease.
- Isolated mitochondrial respiratory chain complex deficiency
- Combined oxidative phosphorylation defect
- Pyruvate dehydrogenase deficiency
- Primary coenzyme Q10 deficiency
- Trifunctional protein deficiency
- Progressive external ophthalmoplegia/Hereditary optic neuropathy
- Ethylmalonic/methylglutaconic encephalopathy
- Biotin-thiamine- responsive encephalopathy
- Myopathy with lactic acidosis
- Alpers-Huttenlocher syndrome
- mtDNA depletion syndrome
- Leigh syndrome
- Barth syndrome
- Perrault syndrome
- Sengers syndrome
- Berardo A, DiMauro S, Hirano M. A diagnostic algorithm for metabolic myopathies. Curr Neurol Neurosci Rep 2010; 10:118-26.
- Darras BT, Friedman NR. Metabolic myopathies: a clinical approach; part I. Pediatr Neurol 2000; 22:87-97.
- van Adel BA, Tarnopolsky MA. Metabolic myopathies: update 2009. J Clin Neuromuscul Dis 2009; 10:97-121.